Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)

NCT ID: NCT03620838

Last Updated: 2019-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-01

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present multi-center study aimed to evaluate whether endometrioma-associated decline in ovarian reserve is progressive in the absence of an intervention and is greater in magnitude than the natural decline over time. Also the affect of endometrioma treatment modalities like surgery or medical on the ovarian reserve over time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

While there is now a proven, prominent relationship between endometriosis and infertility, the exact mechanism of this relationship is still unclear. The relationship between endometriosis and infertility has been increasingly investigated in recent years. Infertility can be explained in those patients with advanced disease, which causes disturbance of the pelvic anatomy and will also prevent tubal passage, but the mechanism at the early stage of endometriosis has not yet been elucidated.

It has been shown that patients with endometriomas have low quantitative ovarian-reserve tests. It has also been shown with oocyte donation studies that endometriosis may be accompanied by a quantitative decrease in oocyte quality defects which may further adversely affect existing ovarian reserves. There are still debates as to whether the presence of endometriomas and the availability of endometriomas itself reduces the over-reserve, but there is no objective study or data on the subject.There are a number of studies that endometriosis may negatively affect the reserve, and also that surgery may cause further damage to the ovarian reserve.There is still lack of definite data for the affect of endometriomas per se and endometriomas treatment modalities ( Oral contraceptive pills (OCP) / progesterone or surgery)on the ovarian reserve over time. For this reason the investigators aimed to evaluate whether endometrioma-associated decline in ovarian reserve is progressive in the absence of any intervention and is greater in magnitude than the natural decline over time. Also the affect of endometrioma treatment modalities like surgery or medical on the ovarian reserve over time.

The study is planned as a prospective study including women with endometrioma diagnosed with ultrasonography and also healthy age matched women without endometriomas as the control group. Endometrioma patients will be divided to 4 subgroups of patients. The first group will be comprised women with endometriomas that who will not require any medical or surgical intervention, the second subgroup will be comprised from endometrioma patients will be treated with OCP during the study period, the third one will be comprised from endometrioma patients will be treated with progesterone and the last subgroup will be comprised from endometrioma patients who will be treated with surgical excision of the cyst. All of the patients with and without endometrioma will be evaluated with ultrasonography for Antral Follicle Count (AFC) and blood samples will be taken during recruitment for Anti-müllerian Hormone (AMH) values. Additional assessments will be done after 3 and 6 months after the first assessment. All the results will be statistically compared within the groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Reserve Endometrioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Patients with endometrioma who had at least one endometrioma \>3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed

No interventions assigned to this group

Group 2

Patients with endometrioma who had at least one endometrioma \>3 cm and who will be treated with OCP during the study period

oral contraceptive pill, oral progesterone

Intervention Type DRUG

ovarian endometrioma cyst excision

Group 3

Patients with endometrioma who had at least one endometrioma \>3 cm and who will be treated with oral progesterone during the study period

oral contraceptive pill, oral progesterone

Intervention Type DRUG

ovarian endometrioma cyst excision

Group 4

Patients with endometrioma who had at least one endometrioma \>3 cm and who will be treated with surgery short after recruitment

oral contraceptive pill, oral progesterone

Intervention Type DRUG

ovarian endometrioma cyst excision

Group 5

The control group, who do not have endometrioma and any gynecological disorder

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oral contraceptive pill, oral progesterone

ovarian endometrioma cyst excision

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

surgery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women between 18 and 40 years of age
* Who had at least one endometrioma \>3 cm

Exclusion Criteria

* İrregular periods
* Polycystic ovarian syndrome
* Pregnant patients
* Patients unable to give informed consent • Using medication which could affect ovarian function during six months before recruitment
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uludag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

GÜRKAN UNCU,PROF. MD

Principal Investigator ; Prof. Dr. Gürkan Uncu

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uludag University Scholl of medicine

Bursa, Turkey/bursa, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

GÜRKAN UNCU

Role: primary

0224 2952541

References

Explore related publications, articles, or registry entries linked to this study.

Aslan K, Kasapoglu I, Kosan B, Gurbuz TB, Muzii L, Uncu G. Impact of endometrioma management strategies on ovarian reserve over the follow-up period, a prospective longitudinal study. Front Endocrinol (Lausanne). 2025 Sep 11;16:1631108. doi: 10.3389/fendo.2025.1631108. eCollection 2025.

Reference Type DERIVED
PMID: 41019321 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Uludag University

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.